ReP USP - Resultado da busca

Artigo de periodico
Repurposing an atherosclerosis targeting peptide for tumor imaging (2022)
Kovacs, Luciana; Davis, Ryan A; Ganguly, Tanushree; Chammas, Roger ; Sutcliffe, Julie L
Source: Biomedicine & pharmacotherapy. Unidade: FM
Subjects: DOENÇA CRÔNICA, NEOPLASIAS, ATEROSCLEROSE, PEPTÍDEOS, PROLIFERAÇÃO CELULAR
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
KOVACS, Luciana et al. Repurposing an atherosclerosis targeting peptide for tumor imaging. Biomedicine & pharmacotherapy, v. 145, 2022Tradução . . Disponível em: https://doi.org/10.1016/j.biopha.2021.112469. Acesso em: 16 nov. 2024.
APA
Kovacs, L., Davis, R. A., Ganguly, T., Chammas, R., & Sutcliffe, J. L. (2022). Repurposing an atherosclerosis targeting peptide for tumor imaging. Biomedicine & pharmacotherapy, 145. doi:10.1016/j.biopha.2021.112469
NLM
Kovacs L, Davis RA, Ganguly T, Chammas R, Sutcliffe JL. Repurposing an atherosclerosis targeting peptide for tumor imaging [Internet]. Biomedicine & pharmacotherapy. 2022 ; 145[citado 2024 nov. 16 ] Available from: https://doi.org/10.1016/j.biopha.2021.112469
Vancouver
Kovacs L, Davis RA, Ganguly T, Chammas R, Sutcliffe JL. Repurposing an atherosclerosis targeting peptide for tumor imaging [Internet]. Biomedicine & pharmacotherapy. 2022 ; 145[citado 2024 nov. 16 ] Available from: https://doi.org/10.1016/j.biopha.2021.112469
Artigo de periodico
From dual binding site acetylcholinesterase inhibitors to allosteric modulators: a new avenue for disease-modifying drugs in Alzheimer's disease (2017)
Chierrito, Talita P. C.; Mantoani, Susimaire Pedersoli; Roca, Carlos; Requena, Carlos; Perez, Victor Sebastian; Castillo, Willian O.; Moreira, Natalia C. S.; Pérez, Concepción; Sakamoto-Hojo, Elza Tiemi; Takahashi, Catarina Satie; Barbero, Jesús Jiménez; Cañada, F. Javier; Campillo, Nuria E.; Martinez, Ana; Carvalho, Ivone
Source: European Journal of Medicinal Chemistry. Unidades: FFCLRP, FCFRP
Subjects: DOENÇA DE ALZHEIMER, INIBIDORES DE ENZIMAS, PROLIFERAÇÃO CELULAR
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
CHIERRITO, Talita P. C. et al. From dual binding site acetylcholinesterase inhibitors to allosteric modulators: a new avenue for disease-modifying drugs in Alzheimer's disease. European Journal of Medicinal Chemistry, v. 139, p. 773-791, 2017Tradução . . Disponível em: https://doi.org/10.1016/j.ejmech.2017.08.051. Acesso em: 16 nov. 2024.
APA
Chierrito, T. P. C., Mantoani, S. P., Roca, C., Requena, C., Perez, V. S., Castillo, W. O., et al. (2017). From dual binding site acetylcholinesterase inhibitors to allosteric modulators: a new avenue for disease-modifying drugs in Alzheimer's disease. European Journal of Medicinal Chemistry, 139, 773-791. doi:10.1016/j.ejmech.2017.08.051
NLM
Chierrito TPC, Mantoani SP, Roca C, Requena C, Perez VS, Castillo WO, Moreira NCS, Pérez C, Sakamoto-Hojo ET, Takahashi CS, Barbero JJ, Cañada FJ, Campillo NE, Martinez A, Carvalho I. From dual binding site acetylcholinesterase inhibitors to allosteric modulators: a new avenue for disease-modifying drugs in Alzheimer's disease [Internet]. European Journal of Medicinal Chemistry. 2017 ; 139 773-791.[citado 2024 nov. 16 ] Available from: https://doi.org/10.1016/j.ejmech.2017.08.051
Vancouver
Chierrito TPC, Mantoani SP, Roca C, Requena C, Perez VS, Castillo WO, Moreira NCS, Pérez C, Sakamoto-Hojo ET, Takahashi CS, Barbero JJ, Cañada FJ, Campillo NE, Martinez A, Carvalho I. From dual binding site acetylcholinesterase inhibitors to allosteric modulators: a new avenue for disease-modifying drugs in Alzheimer's disease [Internet]. European Journal of Medicinal Chemistry. 2017 ; 139 773-791.[citado 2024 nov. 16 ] Available from: https://doi.org/10.1016/j.ejmech.2017.08.051
Artigo de periodico
Endostatin neoadjuvant gene therapy extends survival in an orthotopic metastatic mouse model of renal cell carcinoma (2012)
Braga, Marina de Souza; Chaves, Karen Barbosa; Chammas, Roger; Schor, Nestor; Bellini, Maria Helena
Source: Biomedicine & Pharmacotherapy. Unidade: FM
Subjects: NEOPLASIAS RENAIS (CIRURGIA), CARCINOMA (QUIMIOTERAPIA), METÁSTASE NEOPLÁSICA, MODELOS ANIMAIS, PROLIFERAÇÃO CELULAR, CAMUNDONGOS, NEDRECTOMIA, FATORES DE RISCO
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
BRAGA, Marina de Souza et al. Endostatin neoadjuvant gene therapy extends survival in an orthotopic metastatic mouse model of renal cell carcinoma. Biomedicine & Pharmacotherapy, v. 66, n. 4, p. 237-241, 2012Tradução . . Disponível em: https://doi.org/10.1016/j.biopha.2011.11.002. Acesso em: 16 nov. 2024.
APA
Braga, M. de S., Chaves, K. B., Chammas, R., Schor, N., & Bellini, M. H. (2012). Endostatin neoadjuvant gene therapy extends survival in an orthotopic metastatic mouse model of renal cell carcinoma. Biomedicine & Pharmacotherapy, 66( 4), 237-241. doi:10.1016/j.biopha.2011.11.002
NLM
Braga M de S, Chaves KB, Chammas R, Schor N, Bellini MH. Endostatin neoadjuvant gene therapy extends survival in an orthotopic metastatic mouse model of renal cell carcinoma [Internet]. Biomedicine & Pharmacotherapy. 2012 ; 66( 4): 237-241.[citado 2024 nov. 16 ] Available from: https://doi.org/10.1016/j.biopha.2011.11.002
Vancouver
Braga M de S, Chaves KB, Chammas R, Schor N, Bellini MH. Endostatin neoadjuvant gene therapy extends survival in an orthotopic metastatic mouse model of renal cell carcinoma [Internet]. Biomedicine & Pharmacotherapy. 2012 ; 66( 4): 237-241.[citado 2024 nov. 16 ] Available from: https://doi.org/10.1016/j.biopha.2011.11.002

USP Schools

ReP

Filtros

Authors

Subjects

Funding Agencies

Indexado em